12 Month Price Forecast For COCH
Distance to COCH Price Forecasts
COCH Price Momentum
๐ค Considering Envoy Medical (COCH)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 5:41 AM UTC
COCH Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, COCH has a bullish consensus with a median price target of $6.00 (ranging from $5.00 to $9.00). Currently trading at $1.54, the median forecast implies a 289.6% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 484.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COCH Analyst Consensus
COCH Price Target Range
Latest COCH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COCH.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Dec 6, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $9.00 |
Oct 14, 2024 | Brookline Capital | Tyler Bussian | Buy | Initiates | $9.00 |
Sep 3, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $8.75 |
Jun 24, 2024 | Ascendiant Capital | Edward Woo | Buy | Initiates | $8.50 |
Apr 3, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $6.00 |
Dec 21, 2023 | Northland Capital Markets | Carl Byrnes | Outperform | Initiates | $0.00 |
Nov 28, 2023 | Lake Street | Frank Takkinen | Buy | Initiates | $3.00 |
Stocks Similar to Envoy Medical, Inc. - Class A Common Stock
The following stocks are similar to Envoy Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Envoy Medical, Inc. - Class A Common Stock (COCH) Financial Data
Envoy Medical, Inc. - Class A Common Stock has a market capitalization of $32.79M with a P/E ratio of -0.6x. The company generates $302,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +7.9% quarter-over-quarter, while maintaining an operating margin of -7,147.1% and return on equity of N/A.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Envoy Medical, Inc. - Class A Common Stock (COCH) Company Overview
About Envoy Medical, Inc. - Class A Common Stock
Develops innovative medical technologies for hearing loss.
The company generates revenue by providing a range of hearing devices, including personal sound amplification products, hearing aids, and advanced implants. These technologies aim to enhance hearing capabilities and improve the quality of life for individuals with hearing impairments.
Founded in 1995 and headquartered in White Bear Lake, Minnesota, Envoy Medical, Inc. is positioned to transform the hearing industry with its cutting-edge products. The recent name change reflects its commitment to innovation and growth in the hearing health market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
34
CEO
Mr. Brent T. Lucas Esq.
Country
United States
IPO Year
2023
Website
www.envoymedical.comEnvoy Medical, Inc. - Class A Common Stock (COCH) Latest News & Analysis
Envoy Medical Names Seven Investigational Sites for Participation in Its Pivotal Clinical Study
1 month agoEnvoy Medical (NASDAQ: COCH) plans to start initial patient enrollment for its pivotal clinical trial of the Acclaim CI cochlear implant in Q1 2025, selecting seven study sites.
The announcement of clinical trial enrollment for Envoy Medical's Acclaim CI indicates potential revenue growth and product development, which can influence stock performance and investor interest.
The FDA has approved a pivotal trial for a fully implanted cochlear implant, and the AMA has approved CPT codes for an already FDA-approved middle ear implant, signaling growth for the company.
FDA approval for pivotal trials and CPT code endorsements enhance the companyโs growth prospects, potentially driving revenue and investor interest in the medical device sector.
Envoy Medical's Fully Implanted Acclaimยฎ Cochlear Implant Highlighted in Peer-Reviewed Publication
2 months agoA study in Otology & Neurotology highlights early experiences and potential advantages of a new fully implanted cochlear implant, indicating advancements in hearing technology.
The breakthrough cochlear implant could disrupt the medical device market, driving growth for companies involved in hearing technology and attracting investor interest in innovative healthcare solutions.
Envoy Medical (NASDAQ: COCH) announced the European Patent Office granted Patent No. 3858425 for its implantable cochlear implant system.
The grant of the patent enhances Envoy Medical's competitive edge in the hearing health market, potentially boosting revenue and attracting investor interest.
Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device
3 months agoThe Acclaimยฎ Fully Implanted Cochlear Implant presents a new option for hearing loss patients, distinguishing itself from current cochlear implant technology.
The Acclaimยฎ Fully Implanted Cochlear Implant could capture market share in the healthcare sector, potentially boosting sales and stock prices for the company involved.
Envoy Medical (NASDAQ: COCH) will present a corporate overview at the LD Micro Main Event XVII from October 28-30, 2024, by CFO David R. Wells in Los Angeles.
David R. Wells' presentation at a major investor conference could influence Envoy Medical's stock performance, offering insights into company strategy and financial health.
Frequently Asked Questions About COCH Stock
What is Envoy Medical, Inc. - Class A Common Stock's (COCH) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Envoy Medical, Inc. - Class A Common Stock (COCH) has a median price target of $6.00. The highest price target is $9.00 and the lowest is $5.00.
Is COCH stock a good investment in 2025?
According to current analyst ratings, COCH has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for COCH stock?
Wall Street analysts predict COCH stock could reach $6.00 in the next 12 months. This represents a 289.6% increase from the current price of $1.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Envoy Medical, Inc. - Class A Common Stock's business model?
The company generates revenue by providing a range of hearing devices, including personal sound amplification products, hearing aids, and advanced implants. These technologies aim to enhance hearing capabilities and improve the quality of life for individuals with hearing impairments.
What is the highest forecasted price for COCH Envoy Medical, Inc. - Class A Common Stock?
The highest price target for COCH is $9.00 from Edward Woo at Ascendiant Capital, which represents a 484.4% increase from the current price of $1.54.
What is the lowest forecasted price for COCH Envoy Medical, Inc. - Class A Common Stock?
The lowest price target for COCH is $5.00 from at , which represents a 224.7% increase from the current price of $1.54.
What is the overall COCH consensus from analysts for Envoy Medical, Inc. - Class A Common Stock?
The overall analyst consensus for COCH is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $6.00.
How accurate are COCH stock price projections?
Stock price projections, including those for Envoy Medical, Inc. - Class A Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.